Where Is the Breakthrough Point for TIL Therapy?

From a global perspective,TILThe therapy is not a new technology. As early as20Century80In the 1980s, U.S. research institutions isolated from melanoma patients' tumorsTIL, and throughIL-2Reinfusion after expansion.

It can be said that, long before the emergence of immune checkpoint inhibitors,TILThe therapy has already demonstrated clear antitumor activity in solid tumors such as melanoma, with some patients even achieving long-term remission or even clinical cure.

U.S.lovanceAlthough the company was the earliest to possess the relevant technology and engage in its commercial development, it was not until2024Year,lovanceofTILTherapy-related products have only beenFDAApproved for market launch. This is not due to a single technical bottleneck, but rather an obstacle constituted by a combination of factors.

First are safety and clinical thresholds.TraditionalTILTreatment regimens typically require patients to undergo high-intensity lymphodepleting chemotherapy prior to cell infusion, in order to eliminate pre-existing immune cells in the body and make room for the infusedTILfavorable conditions for cells; meanwhile, high-dose combination therapy is also requiredIL-2to maintain cell viability. This combination not only leads to a significant increase in medical costs, but also imposes extremely high demands on patients’ physical fitness, organ function, and hospital qualifications, resulting in prolonged hospital stays,ICUoccupancy, greatly limiting its clinical application.

Next is manufacturing complexity and cost structure.TraditionalTILCell production often relies on feeder cell systems, involving numerous process steps and high levels of manual intervention, which makes standardized scale-up difficult; furthermore, when genetic modification is involved, the use of viral vectors further drives up production and quality control costs. This makesTILThe therapy faces a situation where "the efficacy is captivating, but the cost is prohibitive."

Facing these pervasiveTILAddressing the long-standing challenges in cell therapy from clinical development to manufacturing, Juncell Therapeutics has risen to the occasion and entered this sector.

Juncell Therapeutics adopts a strategy of “industry logic first”:How to Systematically Reduce Safety Risks, Manufacturing Costs, and Clinical Adoption Barriers Without Compromising Therapeutic Potential

This strategy is first reflected in itsDeepTIL™ platform. ByTILReconstruction of Cell Enrichment and Expansion Processes: Juncell Therapeutics Maintains Cell Viability and Quantity While AvoidingTILCells to High ConcentrationIL-2Develop dependence, thereby breaking free fromIL-2Dependence on supportive care. This change is not simply “removing a medication step,” but rather aTILCracking the Long-Standing Safety Concerns Most Criticized in Therapy.

Building on this foundation, Juncell Therapeutics has further reduced the intensity of lymphodepletion, enabling patients to complete treatment without the need for sterile isolation environments, and even exploring day-ward administration pathways. The industrial significance of this shift lies inIt allowsTILThe therapy now has the real potential to expand to hospitals at more levels and reach broader patient populations.

Meanwhile, by leveraging a non-trophoblast cell culture system and non-viral vector technology platforms, Juncell Therapeutics has also significantly streamlined its cost structure on the manufacturing side. This strategic technological choice, which simultaneously impacts both clinical application and manufacturing processes, enablesTILThe therapy offers greater accessibility in real-world settings.

This also explains a practical reality: in the field of solid tumor cell therapy, it is not enough to simply demonstrate “impressive efficacy”; one must also address the issues of “patient accessibility, hospital adoption confidence, and reimbursement system sustainability.”

From GC101 to Platform-Based Layout

If technological choices constitute Juncell'sTILAnswering Industry Challenges, Then Its Core ProductsGC101, is the verification of this logic.

However, Juncell’s ambitions extend far beyond merely “developing a product.”

From the perspective of pipeline layout,GC101It serves more as a “stepping stone,” with its true long-term value lying in supporting a sustainably scalable platform ecosystem.InGC101On this basis, Juncell Therapeutics has advancedGC203This Non-Viral Vector-Mediated Genetic ModificationTILProduct. By introducing membrane-bound, self-assemblingIL-7，GC203Attempt to enhanceTILthe adaptability of cells in vivo and remodel the tumor microenvironment, thereby further amplifying the anti-tumor effect. WithGC203as the basis, further deriving into dual-gene modifiedGC301、GC304pipeline, providing more powerful tools for the treatment of solid tumors.

More forward-looking is based onRiverTIL™ Platform Development EndogenousTILAwaiting the next-generation layout. The core idea of this direction is,OmittedTILSteps for large-scale ex vivo expansion of cells, enablingTILSeed cells undergo self-expansion in vivo, fundamentally shortening treatment wait times and further reducing production costs.

From an industry perspective, the platform potential and capability to evolve from a single product for a single indication to a single product for multiple indications, and further to multiple products with broader indications, determine whether a cell therapy company possesses long-term value.

Unlike the presentCAR-TTherapies are primarily focused on the field of hematologic malignancy treatment, with well-defined and fixed targets, and most are concentrated inCD19、BCMA, after several years of exploration, its technical pathway, manufacturing processes, and clinical applications have become relatively standardized,TILThe selection of the technical pathway for this therapy has enabled a sharper focus on solid tumor cell therapy. Furthermore, the absence of fixed target restrictions, combined with its personalized nature and manufacturing complexity, has raised the barrier to entry in this field; therefore,Currently focused globally onTILTherapy development companies remain few, with listed onesTILThere is only one drug product available, and a large-scale competitive market landscape has not yet formed.

Furthermore,TILThe therapy focuses more on solid tumor cell therapy, and the real threshold lies not in "whether an effective product can be developed," but in whether a technical system capable of continuous output and iteration can be established.

In this sense,TILIn this field, “first to market” is merely the first step; what matters more is who can first establish a complete commercial loop spanning R&D, manufacturing, and reimbursement.

Conclusion

Amid tightening capital for innovative drugs and rapidly diverging technological pathways,IPONo longer a synonym for success. For Juncell Therapeutics, going public is more like a phased assessment—testing whether its judgment on the "feasible pathway" for solid tumor cell therapy holds true.

TILWhether it will become the next mainstream approach in immunotherapy for solid tumors still requires time and key clinical data to provide a definitive answer. However, what is certain is thatAs the industry begins to examine the safety, efficacy, accessibility, and affordability of cell therapy from a broader perspective, solid tumor cell therapy has reached a new starting point.

Juncell Therapeutics is precisely a key case study at this starting point.